Abstract:
Оbjective: To evaluate the clinical efficacy of empagli
flozin in patients with chronic heart failure with reduced
ejection fraction. Material and methods: The study was
conducted at the multidisciplinary clinic of the Tashkent
Medical Academy. The study included 40 patients with
CHF II-IV functional class according to the classification
of the New York Heart Association and reduced ejection
fraction. 16 patients had coronary heart disease, 27 had
arterial hypertension, 7 had combined pathology (CHD
+ hypertension), 8 had type 2 diabetes mellitus. The av
erage age of patients was 59.2 ± 7.5 years. Results: The
inclusion of empagliflozin in standard therapy for chronic
heart failure with reduced ejection fraction demonstrated
a decrease in NT-proBNP levels, an increase in left ventric
ular ejection fraction, a decrease in heart failure symp
toms and an improvement in the results of the six-minute
walk test, which together contributed to an improvement
in the quality of life of patients. Conclusions: Timely and
competent therapy can not only restore the left ventric
ular ejection fraction, but also improve the prognosis of
patients.
